Status:

COMPLETED

A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Precancerous Gastric Lesions

Eligibility:

All Genders

35-65 years

Phase:

PHASE3

Brief Summary

The Division of Cancer Epidemiology and Genetics is conducting a collaborative randomized multi-intervention trial with the Beijing Institute for Cancer Research to evaluate the etiologic role of Heli...

Detailed Description

The Division of Cancer Epidemiology and Genetics is conducting an 8-year collaborative randomized multi-intervention trial with the Beijing Institute for Cancer Research to evaluate the etiologic role...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Ages 35-670 in the 14 Linqu villages who received endoscopy examinations in the fall of 1994.
  • Both men and women will be included.
  • Patients must sign an informed consent form indicating a willingness to participate in the 42-month trial.
  • Must be free of debilitating chronic disease.
  • Must not report allergies to penicillin or similar medications.
  • Must not have had previous treatment for H. pylori.
  • Must not have a history of bleeding disorder.
  • Must not be taking vitamin/mineral supplements on a regular basis.
  • EXCLUSION CRITERIA:
  • Persons with cancer (except resected non-melanotic skin cancer), heart failure, emphysema, and other life-threatening illness will be excluded.

Exclusion

    Key Trial Info

    Start Date :

    July 1 1995

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 10 1996

    Estimated Enrollment :

    3411 Patients enrolled

    Trial Details

    Trial ID

    NCT00339768

    Start Date

    July 1 1995

    End Date

    June 10 1996

    Last Update

    December 12 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Beijing Institute for Cancer Research

    Beijing, China